Led · Equity · Aug 2026

Vedanta's lead program, VE303, is an orally administered live biotherapeutic product comprising a defined consortium of eight bacterial strains, developed to prevent recurrent Clostridioides difficile infection. VE303 is produced from pure, clonal bacterial cell banks to yield a standardized powdered drug product and has received FDA Orphan Drug designation (2017) and Fast Track designation (2023). The registrational Phase 3 RESTORATiVE303 trial is randomized, double-blind and placebo-controlled with a 2:1 randomization and a primary endpoint of CDI recurrence rate at Week 8. RESTORATiVE303 is enrolling across more than 150 sites in about 20 countries, has passed a DMC interim analysis recommending continuation, and is expected to complete enrollment in H2 2026 with topline data in H1 2027. Vedanta is funding the trial through the recent $60M financing package and supplemental BARDA funding. The company intends the RESTORATiVE303 study to form the basis for a Biologics License Application to the U.S. FDA.

Led · Series B · Jul 2026

Founded in late 2022 and headquartered in Singapore, Rize operates a rice supply-chain platform that provides agronomic support, technology tools, and market access to smallholder farmers. The company works with nearly 17,000 farmers across more than 50,000 hectares in Indonesia and Vietnam and has expanded operations more than tenfold over the past two years. Rize has exported 1,500 metric tonnes of low-emission rice to buyers in Europe, Canada, Australia, and Singapore and is pursuing further regional expansion. It is building a carbon business around sustainable rice cultivation; its projects have an A.pre ex-ante rating from BeZero Carbon and are undergoing Gold Standard certification, with the potential to generate over one million carbon credits in the next five years. Rize promotes the Alternate Wetting and Drying irrigation method to cut methane emissions, reduce water use, and increase farmer incomes while maintaining yields.

Participated · Equity · Mar 2026

Sistema.bio is described as a Mexican biogas firm that has launched FarmCarbon, a climate finance vehicle tied to carbon markets. The company secured $53 million to support FarmCarbon, which is intended to channel carbon market revenues to smallholder farmers. The article does not provide additional detail on Sistema.bio’s core products, revenue, user metrics, or founding year. It also does not disclose participating investors or prior financing rounds. The disclosed funding indicates an active move into climate finance mechanisms linked to the carbon market.

Participated · Series B · Feb 2026

ILiAD Biotechnologies is focused on eradicating whooping cough by advancing BPZE1, its next-generation live-attenuated intranasal pertussis vaccine. BPZE1 is designed to induce both systemic and mucosal immunity, offering durable protection that current acellular vaccines fail to provide. Across six completed clinical studies, including a human challenge trial published in The Lancet Microbe, the vaccine has shown promising safety and immunogenicity data. The company plans to initiate a pivotal Phase 3 human challenge study in 2026, with initial results expected in 2027, and it ultimately intends to expand indications to neonates. Proceeds from its recent financing will fund Phase 3 development and associated manufacturing and regulatory activities. ILiAD collaborates with leading scientists and leverages proprietary technologies to overcome the limitations of existing pertussis vaccines. The company highlights the global need for better solutions, noting that pertussis still affects about 24 million people annually and causes nearly 160,000 deaths in children under five despite 84 % vaccination coverage worldwide.

Participated · Equity · Feb 2021

ReNew Power Private Limited entered into a subscription agreement to issue 85,500,000 common shares at $10 per share for gross proceeds of $855,000,000 on February 24, 2021. The transaction included participation from institutional investors and funds/accounts managed by BlackRock, Parvest SICAV - Energy Innovators (a fund managed by BNPP Asset Management Luxembourg), TT International Funds plc - TT Environmental Solutions Fund (managed by TT International Investment Management LLP), Zimmer Partners, LP, Sylebra Capital Management, and individual investor Chamath Palihapitiya. The company will issue a 19.6% stake at a post-money equity valuation of $4,370,000,000. The board of directors has approved the transaction. Completion is subject to customary closing conditions, including approval from the Competition Commission of India and of the stockholders of RMG II. The transaction is expected to close in the second quarter of 2021, and the shares will be issued relying on the exemption under Section 4(a)(2) of the Securities Act and/or Regulation D. ReNew Power, founded in 2011, is one of India’s leading clean-energy independent power producers with a portfolio across wind, utility-scale solar and rooftop solar. The company is focused on growing capacity through acquisitions and project development to meet India’s increasing electricity demand. CPPIB’s capital is being used to support ReNew Power’s acquisition of Ostro Energy, which adds more than 1,100 megawatts of capacity. With Ostro’s assets, ReNew Power’s total capacity will increase to more than 5,600 megawatts. Management states the company aims to change India’s energy portfolio by delivering cleaner and smarter energy choices and reducing the country’s carbon footprint. The company has expanded its partnership with institutional investors to accelerate growth and strengthen its market position. ReNew Power, founded in 2011 and led by Chairman and CEO Sumant Sinha, is a renewable energy developer and independent power producer based in Gurgaon, Haryana, India. The company develops and operates clean-energy capacity across wind, utility-scale solar and rooftop solar assets. It has close to 3,000 MW of commissioned and under-construction capacity, of which more than 2,000 MW are already commissioned. ReNew operates across thirteen Indian states, including Gujarat, Haryana, Maharashtra, Karnataka and Telangana. The article provides operating metrics (capacity and geographic footprint) but does not disclose revenue or profitability. The company recently received a major external equity investment.